EICHORCondition: NASH · Cirrhosis, Liver · Sponsor: Madrigal Pharmaceuticals, Inc.
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham (UAB) | Birmingham, Alabama, United States | — |
| Arizona Liver Health - Chandler | Chandler, Arizona, United States | — |
| Arizona Liver Health - Peoria | Peoria, Arizona, United States | — |
| Adobe Clinical Research | Tucson, Arizona, United States | — |
| Arizona Liver Health - Tucson | Tucson, Arizona, United States | — |
| Arkansas Diagnostic Center/Liver Wellness Center | Little Rock, Arkansas, United States | — |
| Arkansas Gastroenterology | North Little Rock, Arkansas, United States | — |
| Southern California Research Center | Coronado, California, United States | — |
| University of California, San Francisco-Fresno | Fresno, California, United States | — |
| Univ. of California San Diego School of Medicine | La Jolla, California, United States | — |
| Keck School of Medicine of USC | Los Angeles, California, United States | — |
| Knowledge Research Center | Orange, California, United States | — |
+ 129 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05500222